JOHN DAVID HANSEN Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for JOHN DAVID HANSEN.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of JOHN DAVID HANSEN. JOHN DAVID HANSEN is V.P. of Corporate Development in AVANIR PHARMACEUTICALS, INC. ($AVNR) and President and CEO in MABVAX THERAPEUTICS HOLDINGS, INC. ($MBVX).
Latest Insider Trading Transactions of JOHN DAVID HANSEN
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 23 2018 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | A | 2.04 | 290,000 | 591,600 | 290,000 | |
Feb 23 2018 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | A | 2.04 | 290,000 | 591,600 | 290,000 | |
Jan 18 2018 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Sell | S | 0.92 | 59,263 | 54,522 | 536,730 | 596 K to 536.7 K (-9.94 %) |
Jan 16 2018 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | M | 0.00 | 727,210 | 0 | 0 | |
Jan 16 2018 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Sell | S | 0.96 | 18,582 | 17,839 | 595,993 | 614.6 K to 596 K (-3.02 %) |
Jan 16 2018 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Sell | S | 0.98 | 64,015 | 62,735 | 614,575 | 678.6 K to 614.6 K (-9.43 %) |
Jan 16 2018 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Sell | S | 0.96 | 110,093 | 105,689 | 678,590 | 788.7 K to 678.6 K (-13.96 %) |
Jan 16 2018 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Buy | M | 0.00 | 727,210 | 0 | 788,683 | 61.5 K to 788.7 K (+1,182.97 %) |
Oct 04 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | A | 0.00 | 551,156 | 0 | 551,156 | |
Sep 18 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | A | 0.00 | 176,054 | 0 | 176,054 | |
Aug 02 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | S | 6.29 | 3,119 | 19,619 | 0 | |
Aug 02 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | S | 5.55 | 3,119 | 17,310 | 0 | |
Aug 02 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Buy | P | 0.00 | 4,842 | 0 | 70,601 | 65.8 K to 70.6 K (+7.36 %) |
Aug 02 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Buy | P | 1.75 | 4,286 | 7,501 | 65,759 | 61.5 K to 65.8 K (+6.97 %) |
May 23 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | A | 2.00 | 500,000 | 1,000,000 | 500,000 | |
Apr 14 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Sell | S | 2.00 | 10,216 | 20,433 | 61,473 | 71.7 K to 61.5 K (-14.25 %) |
Apr 11 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Sell | S | 2.00 | 250 | 500 | 71,689 | 71.9 K to 71.7 K (-0.35 %) |
Apr 11 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Sell | S | 2.00 | 560 | 1,120 | 71,939 | 72.5 K to 71.9 K (-0.77 %) |
Apr 11 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Sell | S | 2.01 | 666 | 1,335 | 72,499 | 73.2 K to 72.5 K (-0.91 %) |
Apr 06 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Sell | S | 2.15 | 1,501 | 3,223 | 73,165 | 74.7 K to 73.2 K (-2.01 %) |
Apr 06 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Sell | S | 2.15 | 2,450 | 5,271 | 74,666 | 77.1 K to 74.7 K (-3.18 %) |
Apr 06 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Sell | S | 2.25 | 1,100 | 2,475 | 77,116 | 78.2 K to 77.1 K (-1.41 %) |
Apr 04 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | M | 0.00 | 40,687 | 0 | 40,687 | |
Apr 04 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Buy | M | 0.00 | 40,687 | 0 | 78,216 | 37.5 K to 78.2 K (+108.41 %) |
Feb 08 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | A | 2.99 | 250,000 | 747,500 | 250,000 | |
Jan 03 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | A | 3.38 | 63,400 | 214,292 | 63,400 | |
Aug 30 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | A | 5.00 | 63,400 | 317,000 | 63,400 | |
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | P | 6.29 | 3,119 | 19,619 | 3,119 | |
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | P | 5.55 | 3,119 | 17,310 | 3,119 | |
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Buy | P | 0.00 | 3,119 | 0 | 37,529 | 34.4 K to 37.5 K (+9.06 %) |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | M | 0.00 | 301,184 | 0 | 602,166 | |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Payment of Exercise | F | 0.00 | 113,148 | 0 | 254,634 | 367.8 K to 254.6 K (-30.76 %) |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Buy | M | 0.00 | 301,084 | 0 | 367,782 | 66.7 K to 367.8 K (+451.41 %) |
Feb 18 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | A | 0.49 | 500,000 | 245,000 | 500,000 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | President and CEO | Option Exercise | A | 0.00 | 903,250 | 0 | 903,250 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | President and CEO | Option Exercise | A | 2.30 | 903,250 | 2,077,475 | 903,250 | |
Jan 03 2005 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Sell | S | 3.40 | 10,200 | 34,680 | 15,000 | 25.2 K to 15 K (-40.48 %) |
Jan 03 2005 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Sell | S | 3.39 | 4,800 | 16,254 | 25,200 | 30 K to 25.2 K (-16.00 %) |
Jan 03 2005 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Sell | S | 3.42 | 600 | 2,052 | 15,000 | 15.6 K to 15 K (-3.85 %) |
Jan 03 2005 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Sell | S | 3.41 | 14,400 | 49,044 | 15,600 | 30 K to 15.6 K (-48.00 %) |
Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Option Exercise | A | 3.46 | 50,000 | 173,000 | 50,000 | |
Sep 14 2004 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Sell | S | 3.15 | 15,000 | 47,259 | 30,000 | 45 K to 30 K (-33.33 %) |
Sep 14 2004 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Sell | S | 3.15 | 15,000 | 47,259 | 30,000 | 45 K to 30 K (-33.33 %) |
Apr 08 2004 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Option Exercise | A | 1.78 | 10,000 | 17,800 | 10,000 |
Page: 1